SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

HBAR is trending due to news of the first Hedera ETF being listed on the NYSE, despite a broader US shutdown, sparking excitement within the community. Talk centers on enterprise use cases and potential institutional adoption, with some anticipating a "sell the news" event while others remain bullish on long-term prospects.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending due to a mix of analyst ratings and community sentiment regarding future performance; Northland Securities raised its price target, while others maintain lower targets. Discussions revolve around the impact of deferred revenue and potential earnings beats, with many investors weighing the impact of Jim Cramer's negative sentiment. Overall, the community is focused on Super Micro Computer's potential in the AI infrastructure market amid concerns about management's execution.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending ahead of earnings, with community members anticipating a strong report and discussing potential price movements. Optimism is fueled by upcoming catalysts like potential rate cuts and the possibility of crypto integration. Investors are closely watching for guidance and signals about the company's long-term growth trajectory.

Digi Power X, Inc. is a block chain technology company, which engages in crypto currency mining. It focuses on validation through mining, hosting solutions, and blockchain software solutions. It operates through the following segments: Cryptocurrency Mining, Sales of Energy and Electricity, and Colocation Services. The company was founded on February 18, 2017, and is headquartered in Miami, FL.

Digi Power X Inc. - Ordinary Shares (Sub voting)

Digi Power X ($DGXX) is trending as investors focus on its AI infrastructure and data center initiatives, particularly its partnership with Super Micro Computer (SMCI). Community discussions highlight the company's strategic shift towards AI/HPC, its ownership of power assets, and the potential for significant growth in the AI infrastructure market. Some are pointing to legendary investor Peter Lynch owning a considerable position in the company as well.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Shares of Intellia Therapeutics are trending due to a significant drop following a pause in late-stage trials for their leading therapy, nex-z, after a patient experienced liver problems; however, some investors view this as an overreaction and a buying opportunity, especially given Cathie Wood's recent purchase of a large number of shares. The community is actively debating whether the decline is justified and discussing potential recovery catalysts. Some traders are also noting a high short interest and anticipating a potential short squeeze.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies in anticipation of a large token burn at 3000 watchers, which they believe will trigger a bullish shift. Community members highlight the project's commitment to organic growth, transparency, and consistent development within the Solana ecosystem. They are drawing comparisons to Gamestop's historical pump, with the goal of achieving financial freedom.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending as investors discuss its integral role in the AI and semiconductor sectors, particularly with potential benefits arising from recent partnerships and increased demand for advanced chip manufacturing equipment. Community discussions revolve around its monopolistic position and future growth prospects, balanced with concerns about valuation and geopolitical factors affecting the sector. Additionally, analysts are weighing in with upgrades and target adjustments, influencing market sentiment.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

LUMN is trending due to growing excitement around its potential role in the AI race and a recent partnership, sparking discussions of a short squeeze and significant upside. Community members are actively debating its future earnings potential, with some eyeing specific price targets and others seeing it as a long-term play. Bullish sentiment is fueled by BlackRock's ownership and the perception that LUMN is undervalued given its essential infrastructure.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

GLD is trending as traders assess the recent pullback in gold prices, with community members debating potential support levels and entry points. Discussions include the impact of US-China trade talks, potential Federal Reserve actions, and broader macroeconomic factors on gold's outlook. Some traders are considering GLD as a hedge against market uncertainty, while others believe it is overbought and due for a correction.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Cybin Inc

Cybin is trending amid discussions about a recent financing agreement and its potential impact on the stock's value, with some community members expressing concern over possible dilution. Despite this, optimism persists around Cybin's clinical trials, particularly its Phase 3 program, and its position within the psychedelic therapeutics sector. The community is weighing the company's prospects against those of its competitors like CMPS and ATAI.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fate Therapeutics (FATE) Reports Q2 Loss, Beats Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of +17.14% and +190.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +32.00% and +21.29%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Health Catalyst (HCAT) Q2 Earnings and Revenues Beat Estimates

Health Catalyst (HCAT) delivered earnings and revenue surprises of +33.33% and +0.24%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 0.00% and -48.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report?

Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Shares of Fate Therapeutics, Inc. (FATE) were in the spotlight on Monday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.fatetherapeutics.com/news-releases/news-release-details/fate-therapeutics-receives-regenerative-medicine-advanced">said</a> that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its FT819.FT819 is an investigational and human-induced pluripotent stem cell-derived CAR T-cell product candidate in Phase 1 clinical development for treating active moderate to severe lupus, an autoimmune disease that can affect many parts of the body.CEO Bob Valamehr said that the designation recognises the therapy's potential in treating lupus. The designation allows for early interactions with the FDA and potential priority review of a product’s biologics license application requesting approval to market a biologic product, the company said.The clinical-stage biopharmaceutical company’s application for the designation included initial clinical safety and activity data from patients treated with FT819 in the ongoing phase 1 clinical trial, it said.The company added that additional clinical data from the study will be reported later in 2025.The clinical development of FT819 is supported by a $7.9 million grant from the California Institute of Regenerative Medicine (CIRM).FATE shares, however, fell by about 13% on Monday morning following the announcement.On Stocktwits, retail sentiment around Fate Therapeutics rose marginally within the ‘extremely bullish’ territory over the past 24 hours while message volume remained ‘high’.<figure class="image"><img style="aspect-ratio:650/147;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_14_at_10_32_53_AM_png_812d8deaf1.webp" alt="FATE's Sentiment Meter and Message Volume as of 10:30 a.m. ET on April 14, 2025 | Source: Stocktwits" width="650" height="147"><figcaption>FATE's Sentiment Meter and Message Volume as of 10:30 a.m. ET on April 14, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/FATE">FATE stock</a> is down by about 49% year-to-date and 84% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/soleno-launches-tablets-for-treating-hyperphagia-in-prader-willi-syndrome/chfC4VARbaE">Soleno Launches Pill For Hyperphagia In Prader-Willi Syndrome Patients But Retail’s Unmoved</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Fate Therapeutics Stock Draws Investor Attention After FDA Grants Special Designation To Its CAR T-Cell Therapy: Retail Stays Optimistic

CEO Bob Valamehr said the RMAT designation recognises the therapy's potential in treating lupus.

Equity

CEO Bob Valamehr said the RMAT designation recognises the therapy's potential in treating lupus.


Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts

Latest Ratings for FATE
 DateFirmActionFromTo Mar 2022HC Wainwright & Co.MaintainsBuy Dec 2021Morgan StanleyMaintainsEqual-Weight Dec 2021WedbushUpgradesNeutralOutperform
 View More Analyst...

FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the Firm

FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the Firm FATE SHAREHOLDER ALERT: Kaskela...

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Fate Therapeutics Inc

Will Alphabet ($GOOGL) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Alphabet Inc Class A

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.29	--	--	N/A
Q2 '25	-$0.35	-$0.29	17.34%	BEAT
Q1 '25	-$0.38	-$0.32	16.52%	BEAT
Q4 '24	-$0.43	-$0.44	-1.64%	MISSED
Q3 '24	-$0.42	-$0.40	3.95%	BEAT

FATE
Fate Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest FATE News

FATEFate Therapeutics Inc